Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06143631 · ClinicalTrials.gov registry record · Phase 4

Prescription of Letrozole for Uterine Myoma

A Phase 4 study of Leiomyoma and Fibroid Uterus, sponsored by University of California, San Francisco.

Recruiting
Registry status
Phase 4
Development phase
140
Enrollment target
5
Study locations

NCT06143631 is a Phase 4 study of Leiomyoma and Fibroid Uterus that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 140 participants, above the 88-participant average among 8 other Leiomyoma trials with a reported enrollment target (59% higher). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06143631, a Phase 4 study of Leiomyoma and Fibroid Uterus, is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
Phase 4
Development phase
140 participants
Enrollment target
5
Study locations

Study Summary

The PLUM Study is a randomized, double-blinded, 2-arm, parallel-group, placebo-controlled trial is designed to compare the efficacy of letrozole versus placebo on leiomyoma-related symptoms and quality of life as well as leiomyoma and uterine size.

Interventions

  • OTHER Placebo
  • DRUG Letrozole 2.5mg

Study Locations (5)

California

  • University of California, Los Angeles - Los Angeles
  • University of California, San Francisco - San Francisco

Minnesota

  • Mayo Clinic - Rochester

Mississippi

  • University of Mississippi Medical Center - Jackson

North Carolina

  • Duke University - Durham

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2024-07-24
Est. Completion 2027-04-30
Phase Phase 4

What the Registry Record Tells You About NCT06143631

The ClinicalTrials.gov registry entry for NCT06143631 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 88-participant average among 8 other Leiomyoma trials with a reported enrollment target (59% higher). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Leiomyoma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06143631 reports 5 study locations spanning 4 distinct geographic areas - top geographies include California, Minnesota, Mississippi.

Frequently Asked Questions

What is clinical trial NCT06143631 about?

NCT06143631 is a clinical study titled "Prescription of Letrozole for Uterine Myoma". The PLUM Study is a randomized, double-blinded, 2-arm, parallel-group, placebo-controlled trial is designed to compare the efficacy of letrozole versus placebo on leiomyoma-related symptoms and quality of life as well as leiomyoma and uterine size.

What is the current status of trial NCT06143631?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 140 participants. The study started on 2024-07-24. Estimated completion is 2027-04-30.

What conditions does trial NCT06143631 study?

This clinical trial studies the following conditions: Leiomyoma, Fibroid Uterus, Leiomyoma, Uterine, Fibroid.

What interventions are being tested in trial NCT06143631?

The interventions under investigation include: Placebo (OTHER), Letrozole 2.5mg (DRUG).

Who is sponsoring clinical trial NCT06143631?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06143631 being conducted?

This trial has 5 study locations across California, Minnesota, Mississippi, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Leiomyoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.